Biontech starts the new year with a strong increase in profits

Created: 05/09/2022 13:29

When presenting the new figures, Biontech reaffirmed its sales forecast for its corona vaccine.

© Sebastian Gollnow/dpa

Biontech is growing: The corona vaccine manufacturer was able to increase its profit again.

Other follow-up versions of the previous Covid 19 vaccine are also being tested.

Mainz – The corona vaccine manufacturer Biontech was again able to significantly increase sales and profits in the first quarter.

In the quarter that ended at the end of March, there was a net profit of around 3.70 billion euros in the books after around 1.13 billion euros in the same period last year, as the company announced on Monday in Mainz.

Sales increased from 2.05 billion euros to 6.37 billion euros.

When presenting the new figures, Biontech confirmed its sales forecast for its corona vaccine of EUR 13 billion to EUR 17 billion for the current financial year.

According to their own statements, Biontech and its US partner Pfizer are still examining possible successor versions of the previous Covid 19 vaccine.

Among other things, this involves a vaccine candidate based on the omicron variant and so-called bivalent vaccines that are directed against omicron and other Sars-CoV-2 strains.

An update of the data from the clinical trials that started in January is "expected in the coming weeks and made available to the regulatory authorities," the company said.

more on the subject

Kion exceeds dampened expectations: no prognosis

BASF confirms annual targets - but many risks

Commerzbank better than expected in the first quarter

In the past fiscal year, Biontech had generated a net profit of around 10.3 billion euros.

Sales were almost 19 billion euros.

dpa